Use of MenAfriVac™ (Meningitis A Vaccine) in a Controlled Temperature Chain (CTC) During Campaigns

The need to keep vaccines in a 2°C to 8°C cold chain is a constraining factor for many immunization campaigns due to limited storage capacity and/or ice pack freezing capacity. In 2012, based on a thorough review of scientific data by regulatory authorities and the World Health Organization, the meningitis A vaccine, MenAfriVac®, was deemed acceptable for use for a period of up to four days at temperatures of up to 40°C in a CTC. These three training modules provide countries with guidance on when and how to take advantage of this flexibility.

Author: World Health Organization

Published: 2013

» Visit web page (English)

(Located at

Resource types: Training material

Diseases/vaccines: Meningococcus

Topics: Introduction and service delivery, Disease/vaccine specific information, Cold chain technologies

Regions: Africa